Kornimate/medical-research-clean huggingface dataset:
effects of rtms based on hemodynamic activity for language recovery in early poststroke aphasia

Conditions: Stroke; Aphasia

Summary: the aim of this study is to assess the safety and clinical efficacy of repetitive transcranial magnetic stimulation (rtms) based on hemodynamic brain activity pattern with functional near infrared spectroscopy (fnirs) in early poststroke nonfluent aphasia patients.

most conventional rtms studies employed an inhibitory low frequency protocol for the contralesional homologs of broca's area. in the present randomized controlled trial, investigators will perform fnirs prior to rtms treatment to select the stimulation method. stimulation site (perilesional or contralesional) and frequency (excitatory high or inhibitory low) will be determined by activation pattern from the fnirs with language task in individual patients. the patient who shows a dominant neural activity at perilesional broca's area on fnirs scanning will be randomly allocated into two groups: high frequency stimulation group and sham stimulation group. if a patient shows a dominant neural activity at contralesional homologs of broca's area on fnirs scanning, the patient will be allocated to a low frequency stimulation group.

Eligibility criteria:
inclusion criteria: * 18-80 yrs old * right-handed * radiologically confirmed left hemisphere stroke within 6 months * fluent in korean * first ever stroke * non-fluent (motor-dominant) aphasia * written informed consent exclusion criteria: * previous medical histories of stroke, cerebral vascular operation, * seizure * patients with traumatic brain injury * unable to perform the language task * severe cognitive impairment (mmse less than 16) * skin lesion in the stimulation site of scalp * metal implants in the body (cardiac pacemaker or aneurysm clip) * pregnancy, breastfeeding

Keywords: functional near-infrared spectroscopy stroke aphasia repetitive transcranial magnetic stimulation
the effect of diabetes on the newborn

Conditions: Diabetes

Summary: the aim of this study is to test and compare biochemical, hematological, and inflammatory factors in diabetic and healthy pregnant mothers and in their newborns.


Eligibility criteria:
inclusion criteria: * pregnant women exclusion criteria: -
clonal hematopoiesis on prognosis in patients with myocardial infarction

Conditions: To Investigate the Effect of CHIP on Renal Insufficiency in AMI Patients

Summary: this is an observational study without intervention. it is planned to include 500 patients with ami from october 2023 to july 2026.the study was divided into three parts. part i: to investigate the effect of chip on renal insufficiency in ami patients. part two: to investigate the effect of chip on cardiovascular outcomes in patients with ami complicated with ckd stage ii-iv nephropathy. part three: to investigate the effects of chip on cardiovascular and renal outcomes in ami patients with esrd. study endpoint: primary end points: all-cause death, cardiac death, and nonfatal myocardial infarction. secondary endpoints: angina pectoris requiring hospitalization, nonfatal stroke, and nonfatal heart failure.

this is an observational study without intervention. it is planned to include 500 patients with ami from october 2023 to july 2026.the study was divided into three parts. part i: to investigate the effect of chip on renal insufficiency in ami patients. patients with confirmed ami were divided into two groups based on egfr values: ami+ normal renal function group (egfr≥90 ml/min); ami+ renal dysfunction group (egfr \< 90 ml/min). main outcome measures: chip carrying frequency, expression levels of il-1β, il-6, crp, tnf-α, nlrp3 and other inflammatory factors. part two: to investigate the effect of chip on cardiovascular outcomes in patients with ami complicated with ckd stage ii-iv nephropathy. patients with confirmed ami complicated with ckd stage ii-iv were divided into two groups according to chip sequencing results: chip group: patients diagnosed with ami combined with ckd stage ii-iv underwent pci and were identifi ed as chip carriers by gene targeted sequencing. non-chip group: patients diagnosed with ami combined with ckd stage ii-iv underwent pci and were identified as non-chip carriers by gene targeted sequencing. study endpoint: primary endpoints: all-cause death, cardiac death, nonfatal myocardial infarction,50% decrease in egfr, or eskd. secondary endpoints: angina pectoris requiring hospitalization, nonfatal stroke, and nonfatal heart failure. part iii: to investigate the effects of chip on cardiovascular and renal outcomes in ami patients with esrd. patients with confirmed ami combined with esrd were divided into two groups according to chip sequencing results: chip group: patients diagnosed with ami combined with esrd underwent pci and were identified as chip carriers by gene targeted sequencing. non-chip group: patients diagnosed with ami combined with esrd underwent pci and were identified as non-chip carriers by gene targeted sequencing. study endpoint: primary end points: all-cause death, cardiac death, and nonfatal myocardial infarction. secondary endpoints: angina pectoris requiring hospitalization, nonfatal stroke, and nonfatal heart failure.

Eligibility criteria:
inclusion criteria: patients diagnosed with ami received pci. exclusion criteria: patients with severe heart disease, severe liver and kidney insufficiency, pregnancy, etc.
healthy heart habits

Conditions: Acute Coronary Syndrome; Depression

Summary: approximately 350,000 acute coronary syndrome (acs) patients experience significant depression symptoms each year in the us. post-acs depressed mood interferes with patients making necessary changes to behavioral risk factors (e.g., smoking cessation) and predicts poor medical outcomes. the proposed study will develop an integrated depression and behavioral risk factor reduction intervention for secondary prevention post-acs through an open trial of 20 patients.

depression predicts high rates of morbidity/mortality among acute coronary syndrome (acs) patients. part of this relationship is explained by a poor profile of behavioral risk factors (i.e., smoking,physical activity, medication adherence, diet). an integrated treatment targeting both depressed mood and multiple behavioral risk factors could be highly effective in reducing post-acs mortality. behavioral activation for depression may be an ideal counseling treatment for this since it has recently shown promise for facilitating behavioral risk factor changes in acs patients with depression (k23hl107391). the current study adapts this manual targeting post-acs depressed mood and smoking cessation to target depression and multiple behavioral risk factors post-acs. this study will be an open trial (n=20) to test the feasibility and acceptability of our procedures and obtain initial indications of efficacy. this study hypothesizes that 1) the ba-hd manual and study procedures will be feasible and acceptable to post-acs patients with depressed mood as measured by self-report, recruitment/retention rate, and post- treatment qualitative interviews and 2) that participants will experience clinically significant improvements in depressed mood and behavioral risk factor profile. the long-term goal of this research is to improve long-term survival rates following acs.

Eligibility criteria:
inclusion criteria: * acs diagnosis (diagnosis of unstable angina, st and non-st elevation myocardial infarction) documented in medical record in the preceding 2-12 months * current diagnosis of depression documented in medical record, or clinically administered phq-9 score of 10 or greater documented in the medical record in the preceding 12 months, or ces-d score greater than or equal to 10 * current non-adherence to 1 or more of 4 more behavioral risk factors * willing to make immediate changes to one or more of the relevant behavioral risk factors * age of 18-75 * lives within 1.5 hours of hennepin healthcare * fluent in english. exclusion criteria: * limited mental competency (as indicated in medical chart) * presence of current exacerbation of psychosis/serious mental illness or suicidality * in hospice care * currently attending regular counseling targeting depression or any health behavior change * currently attending a cardiac rehabilitation program (those excluded for being in rehabilitation will be re-contacted after completion)

Keywords: behavioral randomized control trial behavioral activation multiple health behavior change integrated care
sling use and functional mobility in a geriatric population

Conditions: Mobility Limitation

Summary: shoulder slings are commonly worn after shoulder surgery. in geriatric patients, painstaking care is taken to reduce any factors that may increase the chance of experiencing a fall. currently, it is not understood if wearing a sling affects someone's general gait and balance.

following many shoulder operations, patients are immobilized in an bulky sling with non-weight bearing restrictions for periods of up to 6 weeks. this is necessary to allow for soft tissue healing particularly following repair of rotator cuff tears and shoulder replacement surgeries, two common procedures performed in the elderly population. previous studies have shown that natural arm swing plays an essential role in maintaining balance and normal gait patterns. decreased functional mobility and gait impairment has been shown to increase the risk of falls, mortality, and morbidity in an elderly population. however, following upper extremity surgery requiring the use of a sling, targeted therapy for gait and balance training is rarely prescribed. consequently, the investigators wish to assess whether or not sling use impacts functional mobility test scores in an elderly population. the aim of this project is to maximize perioperative functionality in these patients in efforts to prevent any unanticipated secondary injury.

Eligibility criteria:
inclusion criteria: * greater than or equal to 65 years of age exclusion criteria: * younger than 65 years of age * pre-existing cognitive impairment * pre-existing mobility impairment * pre-existing symptomatic upper or lower extremity disease
mr guided laser interstitial thermal therapy for the "minimal invasive" treatment of brain metastasis and primary brain tumors

Conditions: Brain Neoplasms; Brain Tumor; Brain Cancer; Recurrent Brain Tumor

Summary: the purpose of this study is to determine if the stereotactic, mr guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for human brain metastasis and primary brain tumors.

this new "minimally invasive" technique has been tested so far, with success, on animal brain tumor models and on human liver metastasis. the main purpose of this study is to determine if the stereotactic, mr guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for the human brain metastasis and primary brain tumors. as secondary objectives for this clinical study, the following are to be explored: * eventual evaluation of the eventual mid and long term post-intervention complications, * evaluate the contra indication for the technique, * evaluate and optimize clinical and logistic intervention protocols, * evaluate the mean duration for the procedure, * evaluate the mean cost for the procedure the clinical trial will include a statistical sample of 12-18 treatments and will run over a period of 18 months. the inclusion period will be for 6 months and the patients will be followed up during 12 months post intervention. the clinical trial will be performed at the lariboisiere university hospital of paris and the patients will be coming from all the assistance publique de paris ( aphp ) hospitals

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * patients with brain metastasis located in the brain hemispheres * patient with a brain metastasis smaller or equal to 4 cm in diameter * patient with primary brain tumor smaller or equal to 4 cm in diameter * patient previously treated with other therapeutic techniques ( radio-therapy, chemotherapy, immunotherapy) which have failed. exclusion criteria: * patients less than 18 years old, * patients presenting contra indication for mri studies * patient for which the primary cancer is melanoma or kidney tumors * patients having a mean life duration longer than 3 months (due to the primary cancer)

Keywords: mr-guided therapy laser interstitial thermal therapy brain metastasis magnetic resonance thermal imaging (mrti)
effects and mechanism of prolonged continuous theta burst stimulation on neuropathic pain

Conditions: Neuropathic Pain; Repetitive Transcranial Magnetic Stimulation

Summary: neuropathic pain (np) is one type of refractory chronic pain condition,medical treatments for np is limited because of its poorly response. a noninvasive brain-stimulation method called transcranial magnetic stimulation (tms) has garnered interest as an alternative treatment for intractable np potentially through inducing therapeutic brain plasticity.indeed, high-frequency (≥ 5 hz) repetitive tms (rtms) over the primary motor cortex (m1) is suggested to be able to reduce neuropathic pain in randomized controlled studies.overall, the clinical application of rtms in chronic pain is still limited by the response rate,the investigation of rtms protocols is important for improving rtms analgesia. theta burst stimulation (tbs) mimics the bursts of neuronal firing which results in robust long-term potentiation. continuous tbs (ctbs) is designed to decrease excitability, whereby prolonged ctbs (pctbs, i.e. multiple ctbs being delivered continuously) has recently been demonstrated to increase excitability. more importantly, pctbs was found to have comparable or even better analgesic effects than standard 10 hz rtms. these findings together call for more studies to validate the analgesic efficacy of pctbs. in this study, the investigators aim to assess and compare the efficacy of prolonged continuous theta burst stimulation (pctbs) with 10hz rtms in np patients.

the investigators designed a randomized, double-blind, sham-controlled study at 1 center. fifty np patients were randomly assigned to 3 groups. a series of 5 daily pctbs(1200 pulses/session) or 10-hz rtms (1500 pulses/session) of primary motor cortex (m1) or sham stimulation was applied to each patients.

Eligibility criteria:
inclusion criteria: * (1)woman or man over 18 and under 70 years old; （2）pain fulfilling the criteria for probable or definite peripheral neuropathic pain ; (3) pain for at least 3 months, continuous pain (at least four days per week), at least moderate intensity (≥ 4/10 assessed by vas) ; (4) stable pharmacological treatment for pain at least 2 weeks before inclusion; (5) able to cooperate in completing questionnaire. exclusion criteria: * (1) any clinically significant or unstable ongoing medical or psychiatric disorder including major depression; (2) history of substance abuse (alcohol, drugs); (3) past treatment with repetitive transcranial magnetic stimulation (rtms); (4) contraindications to rtms (previous severe head trauma or neurosurgical intervention, past or current epilepsy, active brain tumor, intracranial hypertension, implanted ferromagnetic devices, e.g., cardiac pacemaker, neurostimulator, or cochlear implants); (5) other type of pain more severe than neuropathic pain; (6) any difficulty to fill out questionnaires (due to language or cognitive problems); (7) impossibility to be followed during the time course of the study;
a comparison of two socket sealing collagen matrices for extraction socket management

Conditions: Tooth Loss

Summary: a prospective rct of intact extractions with delayed implant placement comparing extraction socket management effectiveness and office economics of two collagen matrices. soft tissue wound healing will be assessed out to 4-months post-operative, when implants will be placed.

a prospective, randomized, multi-center, controlled clinical study of intact extractions (bony dehiscences \<1/3 socket apico-coronal and mesial-distal dimension) with delayed implant placement. study objective: to compare extraction socket management effectiveness and office economics of a frequently used wound dressing (control) with a soft tissue augmentation matrix (test) in 32-64 subjects 18 -75 years of age with intact (bony dehiscence, if present, \< 1/3 socket dimension) extractions intended for dental implant replacement. following screening subjects will undergo tooth extraction and randomization to either the control or test therapy. after treatment, subjects will be followed until 4- months, the time of implant placement. primary outcome: soft tissue wound healing measured by (1) gap closure and (2) graft containment at all time points.

Eligibility criteria:
inclusion criteria: * subject indicated for anterior tooth extraction (from premolars forward) intended for implant placement. * subjects with essentially intact extraction sockets - bony dehiscences \< 1/3 the depth of socket and mesial-distal width of tooth socket * subjects will have read, understood and signed an institutional review board (irb) approved informed consent form (icf). * subjects must be able and willing to follow study procedures and instructions exclusion criteria: * subjects with healing disorders (i.e., diabetes mellitus, cancer, hiv, bone metabolic diseases) that could compromise wound healing and/ or preclude implant surgery; or who are currently receiving or have received within two months prior to study entry, systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy which could compromise wound healing and preclude periodontal surgery. * subjects taking intramuscular or intravenous bisphosphonates. * subjects who have a known allergy or sensitivity to collagen. * subjects with acute, suppurative lesions with pain, swelling and apical lesions \> 5mm will be excluded, though antibiotic prophylaxis may be employed to reduce infection and provide possible subject reconsideration for inclusion. * heavy smokers/tobacco users defined as those smoking ≥ 10 cigarettes or ≥ 4 cigars or ≥ 4 pipes per day. for non-heavy smokers, smoking ≥ 10 cigarettes or ≥ 4 cigars or ≥ 4 pipes per day is prohibited for the duration of the study. * female subjects who are pregnant or lactating, or who intend to become pregnant during the study duration * subjects participating in other clinical studies involving therapeutic intervention (either medical or dental). * subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
device-guided breathing exercises on blood pressure in diabetic patients

Conditions: Hypertension in Type 2 Diabetes

Summary: rationale: hypertension is an important risk factor of cardiovascular disease, especially in patients with type 2 diabetes mellitus (t2dm). a relatively recent development for the treatment of hypertension is the use of breathing exercises. the investigators' previous studies with a breathing device did not show any positive results. however, these studies and other trials investigating the effects of breathing devices had not a double-blind design. therefore, the investigators want to perform a randomized, double-blind, controlled trial in a population of t2dm patients. objective: to determine the effect of a device slowing breathing (resperate©) on office systolic blood pressure (sbp) in diabetic patients with treated hypertension with moderate bp control. study design: a randomized, double-blind, controlled trial. study population: patients with type 2 diabetes mellitus, over 18 years old and a baseline systolic blood pressure between 140-160 mm hg. intervention: one group receives treatment with a breathing device (resperate©) and the other group receives treatment with a "control" breathing device. the latter device does not try to alter the breathing pattern. main study parameters/endpoints: the effect of the breathing device on sbp is the main study parameter. secondary endpoints include diastolic blood pressure (dbp) and quality of life.


Eligibility criteria:
inclusion criteria: * known t2dm, * over 18 years old, * known hypertension with a systolic bp (sbp) between 130-170 mm hg at the previous visit to the internal outpatient department and at the last visit to the internist (which is the same day as baseline measurement) and treated with one or more anti-hypertensive drugs, which have not been changed for the preceding three months. at baseline the sbp should be between 140-160 mm hg, measured by the investigator. exclusion criteria: * patients with orthostatic hypotension, * known heart failure (nyha iii-iv) and/or patients with pulmonary disease (for example asthma, chronic obstructive pulmonary disease and pulmonary fibrosis), * patients with insufficient knowledge of the dutch language to understand the requirements of the study, * additional criteria were hospitalization in the past 3 months, deafness, blindness and cognitive abilities deemed insufficient for operation of a study device.

Keywords: type 2 diabetes hypertension treatment non-medical
sublingual immunotherapy in patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: to assess the effect and safety of sublingual dermatophagoides farinae drops in adult patients with atopic dermatitis and allergic sensitization to house dust mites.240 adults age 18 to 60 years with atopic dermatitis(objective scoring atopic dermatitis, objective scorad from 10 to 40) are going to be enrolled in a randomized,double-blind,placebo-controlled study.sublingual dermatophagoides farinae drops or placebo is given for 9 months in addition to standard therapy.scorad,average anesis interval,rescue medicine and dlqi will be recorded.

scorad is composed of skin rash area,severity and subjective symptom including pruritus and sleeping quality.skin rash area and severity score are objective scorad(range from 0 to 83).subjective scorad range from 0 to 20 and total scorad range from 0 to 103.

Eligibility criteria:
inclusion criteria: * patients of either sex ,aged from 18 to 60 years. diagnosed of atopic dermatitis. * mild to moderate ad ( \[scorad\] 1o-40) * the results of skin prick tests with dermatophagoides farinae allergen extracts preparation is positive(≥2+) * written informed consent by the subject or legal guardian. * female patients of child-bearing potential must be negative pregnant test on screening and use an appropriate method of contraception. exclusion criteria: * dust mites are not the primary allergens. * pregnant, breastfeeding women or women planned to pregnant within 1 year. * have concurrent skin disease that it could interfere with the study evaluation. * were treated with antihistamines or topical therapy within 7 days of randomization. * have received systemic corticosteroids,leukotriene receptor antagonists or immunosuppressants within 4 weeks of randomization. * have received phototherapy (e.g. uva, uvb) within 4 weeks of randomization. * have a history of immune suppressed diseases(malignant tumor or infection of hiv), autoimmune disease or tuberculosis. * patients with impaired liver function (aspartate aminotransferase and/ or alanine aminotransferase levels 1.5 times the upper limit of normal), impaired renal function(serum creatinine\>normal value) or other severe diseases. * bronchial asthma patients who need treatments with corticosteroids and or β agonists(including injection, oral administration or inhalation) regularly. * patients who need to take β-blockers during research. * have received investigational drugs within 3 months prior to randomization or planned use of other investigational drugs during participation in this study. * have received immunotherapy with dust mite preparation within 3 years prior to randomization. * patients with severe mental disorders.

Keywords: sublingual immunotherapy atopic dermatitis dermatophagoides farinae drops